AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03523832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib and Pregabaline
Description: Single dose versus repetition dose
Study NCT03523832 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03631862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is an orally administrated small molecule receptor tyrosine kinase inhibitor selectively targeting VEGFR-2, showing anti-tumor activity across a broad range of advanced cancers.
Study NCT03631862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP Regimen
Description: CHOP regimen(Cyclophosphamide,Vindesine,Epirubicin,Prednisone)
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
Study NCT03797937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: MRI scanner
Study NCT01993082 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training Intervention
Description: For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.~A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage.
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study NCT04608058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital storytelling training
Description: The digital content in this study is called Diabetes and Bumblebee. It features 35 minutes of animation that provides children with a brief description of the disease, its symptoms and complications, treatment methods, the type of insulin, how to preserve insulin, the importance of nutrition and exercise in treating diabetes as well as efficient communication and collaboration with parents and healthcare providers. Exciting and interactive animations were used to depict the daily life of a adolescence with diabetes.
Study NCT04608058 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine training
Description: The control group received the clinics' routine training include face to face class education.
Study NCT00973141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42160443
Description: Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
Study NCT02367456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04449913 (Glasdegib)
Description: Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
Study NCT02367456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/m2 on Days 1-7 (+/- 3 days for each dose) of a 28 day cycle
Study NCT01972659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
Study NCT02809300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood collection
Study NCT01886014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study NCT01886014 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02111148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Urea and creatinine
Description: the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
Study NCT01972659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulphate
Description: Experimental :~50 mg/kg bolus plus 15 mg/kg continuous infusion
Study NCT02111148 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nitrazine
Description: Nitrazine detection in vaginal wash
Study NCT02111148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5ml saline
Description: the vagina will be washed with 5ml saline and vaginal wash will be collected.
Study NCT03172533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinyl estradiol 0.03mg and dienogest 2 mg (combination)
Description: approved oral contraceptive (Germany): Maxim
Study NCT03172533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: placebo
Study NCT05054400 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: F18 Fluciclovine
Description: Given by IV
Study NCT05054400 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Standard of care
Study NCT01972659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: 4 mg/kg iv bolus at the end of the surgery
Study NCT01972659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: 4 mg/kg iv bolus at the end of the surgery
Study NCT01799902 — intervention group
Intervention type: DRUG
Intervention: Solifenacin
Description: Oral
Study NCT04389060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Two capsule grape seed extract (total 600 mg)
Study NCT04846491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection (high dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study NCT04846491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection (low dose) will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study NCT04846491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: Patients will take TDF orally for the first 48 weeks, and then one can choose to continue the single-TDF treatment up to 144 weeks, or may choose to change to receive peginterferon alfa-2b combined TDF therapy for the later 96 weeks, peginterferon alfa-2b will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 weeks a cycle. And then followed for 24 weeks after treatment.
Study NCT04846491 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Peginterferon alfa-2b injection
Description: Peginterferon alfa-2b injection will be weekly subcutaneous injected for 8 weeks and then stop for 4 weeks, 12 week a cycle, up to 12 cycles (144 weeks) at most. TDF will be taken orally during the whole treatment period. And then followed for 24 weeks after treatment.
Study NCT01233050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol
Description: Preoperative skin antisepsis preparation
Study NCT01233050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine Povacrylex/74% Isopropyl Alcohol
Description: preoperative skin antisepsis preparation
Study NCT04674332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting insulin
Description: long acting insulin analogue once daily at bed time
Study NCT04674332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: multiple dose regimen
Description: intermediate and short acting insulin
Study NCT03142646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
Study NCT04168619 — intervention group
Intervention type: DRUG
Intervention: Discontinue methotrexate
Description: According to the international guideline, patients with Roenigk grade 3a which indicate methotrexate-induced liver injury may continue methotrexate with a repeat biopsy in 6 months. In patients with Roenigk grades 3b or 4, indicate significant liver fibrosis/cirrhosis, methotrexate should be discontinued.
Study NCT04168619 — intervention group
Intervention type: OTHER
Intervention: Medication depends on clinical judgement
Description: Once discontinued methotrexate, based on subject's clinical condition and prescribe alternative treatment
Study NCT02724774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting First Relationships®
Description: PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting.
Study NCT00363116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: daclizumab 1 mg/kg/dose every 14 days for 5 doses
Study NCT04389060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape seed extract
Description: Two capsule grape seed extract (total 600 mg)
Study NCT01358734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine at 75 mg/m\^2/day subcutaneous on Days 1-7
Study NCT00904826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.~The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months.
Study NCT03689725 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music created by A. Vollenweider at least 5 times per week from 33 weeks of gestational age until term-equivalent age
Study NCT00045682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Poliglumex
Description: Given IV
Study NCT00226681 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Telephone Support Protocol
Study NCT00226681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT00698191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic MSC (AlloMSC)
Description: Intervention:~Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.~Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight
Study NCT00088582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide (SOM230), Octreotide (Sandostatin)
Study NCT02973841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono-ease device
Description: insertion of US guided IJV using sono-ease device
Study NCT04427787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib will be administered orally at a dose of 60 mg/day
Study NCT04427787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide will be administrated 120 mg injection every 28 days
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS)
Description: The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:~1. Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.~2. Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialist Audiovestibular Consultation
Description: After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Specialist Audiovestibular Consultation
Description: After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSS Customised Vestibular Physiotherapy
Description: Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.~1. Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.~2. Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physiotherapy Practice
Description: Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: All patients will be reviewed after three months follow-up by the overseeing expert.
Study NCT02704819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up
Description: All patients will be reviewed after three months follow-up by the overseeing expert.
Study NCT02399813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axalimogene filolisbac
Study NCT01358734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
Study NCT01358734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care (BSC)
Description: The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.~BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support
Study NCT03147677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Study NCT03147677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Study NCT03147677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Study NCT03147677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Study NCT01263977 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picco- thermodilution catheter
Description: Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
Study NCT01263977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Picco- thermodilution catheter
Description: Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
Study NCT01539083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 100 mg tablet, orally.
Study NCT01539083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 milligram per square meter (mg/m\^2) solution for injection subcutaneously (SC).
Study NCT01539083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 300 mg/m\^2 orally.
Study NCT01539083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg orally.
Study NCT01539083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 50 mg orally.
Study NCT03546062 — intervention group
Intervention type: OTHER
Intervention: patients treated by HTx
Description: From removed and frozen hearts, authors will conduct a tissue and molecular analysis of possible mechanisms T2DM linked.
Study NCT04773756 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sofosbuvir 400 MG/ Daclatasvir 60mg
Description: Giving these two drugs for treatment of COVID patients
Study NCT01828736 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV: AUC 5 on Day 1 every 21 days
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV: AUC 5 on Day 1 every 21 days
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV, 70 mg/m² BSA on day 1 every 21 days
Study NCT01828736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV, 70 mg/m² BSA on day 1 every 21 days
Study NCT02130297 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Treatment
Description: The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
Study NCT02987556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: Collection of glucose data
Study NCT02987556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring
Description: Collection of glucose data
Study NCT02987556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Insulin Pump
Description: insulin delivery
Study NCT02987556 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External Insulin Pump
Description: insulin delivery